bosentan anhydrous has been researched along with Atrial Fibrillation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouras, G; Cleman, MW; Deftereos, S; Giannopoulos, G; Kaoukis, A; Panagopoulou, V; Papoutsidakis, N; Raisakis, K; Stefanadis, C | 1 |
| Held, M; Jany, BH | 1 |
1 review(s) available for bosentan anhydrous and Atrial Fibrillation
| Article | Year |
|---|---|
The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
Topics: Animals; Atherosclerosis; Atrial Fibrillation; Bosentan; Cardiovascular Diseases; Coronary Artery Disease; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Pulmonary; Phenylpropionates; Predictive Value of Tests; Pyridazines; Receptors, Endothelin; Sulfonamides | 2013 |
1 other study(ies) available for bosentan anhydrous and Atrial Fibrillation
| Article | Year |
|---|---|
Pulmonary hypertension in COPD.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Bosentan; Comorbidity; Coronary Artery Disease; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Sulfonamides; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents | 2013 |